Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer.

Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer. Mol Med Rep. 2019 Feb 11;: Authors: Manoharan V, Karunanayake EH, Tennekoon KH, De Silva S, De Silva K, Angunawela P, Lunec J Abstract Head and neck cancer (HNC) is the leading cancer in Sri Lankan males and second most common cancer among Sri Lankan females. This is the first study, to the best of our knowledge, that has focused on investigating the association between TP53 somatic DNA variants, with p53 protein expression and risk factors in a cohort of Sri Lankan patients with HNC. A total of 44 patients with cancer and 20 healthy controls were studied. In total, 36 genomic DNA sequence variants were found, including several novel variants (two deletions in exons 4 and 6, two in the 3' untranslated region and several intronic variants). A total of 14 tumour samples carried pathogenic TP53 mutations. A random selection of 24 samples was analysed immunohistochemically for p53 protein expression. All the samples with point missense variants were strongly immuno‑positive, whereas, samples with nonsense and frameshift TP53 variants were immuno‑negative for p53 immunohistochemical staining. Although, the human papilloma virus is a known risk factor for HNC, results from the present study identified an absence or lower level of infection in the Sri Lankan cohort. PMID: 30816478 [PubMed - as supplied by publish...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research